Gene therapy applications to cancer treatment

Journal of Biomedicine and Biotechnology

Volumn 2003, Issue 1, 2003, Pages 35-47

  Scholl, Susy M ^a   Michaelis, Silke ^a   McDermott, Ray ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; B7 ANTIGEN; BRCA1 PROTEIN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD 5333; CYCLOOXYGENASE 2 INHIBITOR; ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2; LEUVECTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MUCIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; ONYX 015; ONYX 411; PRODRUG; PROSTATE SPECIFIC ANTIGEN; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; SCH 5850; SCH 58500; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR; VNP 2009;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ADVANCED CANCER; ANTIGENICITY; CANCER; CANCER STAGING; CANCER THERAPY; CELL SPECIFICITY; CELL TRANSFER; CLINICAL RESEARCH; FLU LIKE SYNDROME; GENE THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LENTIVIRINAE; NONHUMAN; POXVIRUS; RETROVIRUS; REVIEW; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SPLEEN CELL; STANDARD; T LYMPHOCYTE; TUMOR CELL CULTURE; TUMOR IMMUNOLOGY; VACCINATION; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; LENTIVIRUS; ONYX; POXVIRIDAE; UNIDENTIFIED RETROVIRUS;

EID: 0038009575     PISSN: 11107243     EISSN: None     Source Type: Journal    
DOI: 10.1155/S1110724303209037     Document Type: Review

References (133)

1. Ménétrier-Caux C, Montmain G, Dieu MC, et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood. 1998;92(12):4778-4791.
2. Swisher SG, Roth JA, Carbone DP. Genetic and immunologic therapies for lung cancer. Semin Oncol. 2002;29(1 suppl 4):95-101.
3. Kigawa J, Sato S, Shimada M, Kanamori Y, Itamochi H, Terakawa N. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells. Gynecol Oncol. 2002;84(2):210-215.
4. Ozols RF. Future directions in the treatment of ovarian cancer. Semin Oncol. 2002;29(1 suppl 1):32-42.
5. Xu M, Lin C, Liang X. Experimental study on combination of Ad-p53 with CDDP of As(2)O(3) in human lung adenocarcinoma cell line GLC-82 [in Chinese]. Zhonghua Yi Xue Za Zhi. 2000;80(9):689-693.
6. Walker J, Quirke P. Biology and genetics of colorectal cancer. Eur J Cancer. 2001;37(suppl 7): S163-S172.
7. Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol. 2000;164(4):2214-2220.
8. Vorburger SA, Hunt KK. Adenoviral gene therapy. Oncologist. 2002;7(1):46-59.
9. Mezzina M, Danos O. Five years of vector service for gene therapy. Trends Genet. 2002;18(3):118-119.
10. Paul S, Regulier E, Rooke R, et al. Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodies. Cancer Gene Ther. 2002;9(5):470-477.
11. Tsang KY, Zhu M, Even J, Gulley J, Arlen P, Schlom J. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells. Cancer Res. 2001;61(20):7568-7576.
12. Hemminki A, Alvarez RD. Adenoviruses in oncology: a viable option? BioDrugs. 2002;16(2):77-87.
13. Hemminki A, Zinn KR, Liu B, et al. In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst. 2002;94(10):741-749.
14. Reid T, Galanis E, Abbruzzese J, et al. Intraarterial administration of a replication-selective adenovirus (d11520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 2001;8(21):1618-1626.
15. Ries S, Korn WM. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer. 2002;86(1):5-11.
16. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (d11520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol. 2002;20(6):1562-1569.
17. Trevor KT, Hersh EM, Brailey J, Balloul JM, Acres B. Transduction of human dendritic cells with a recombinant modified vaccinia ankara virus encoding MUC1 and IL-2. Cancer Immunol Immunother. 2001;50(8):397-407.
18. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 2000;6(5):1632-1638.
19. Adams M, Borysiewicz L, Fiander A, et al. Clinical studies of human papilloma vaccines in preinvasive and invasive cancer. Vaccine. 2001;19(17-19):2549-2556.
20. Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant nonreplicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine. 1997;15(6-7):759-768.
21. Estcourt MJ, Ramsay AJ, Brooks A, Thomson SA, Medveckzy CJ, Ramshaw IA. Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population. Int Immunol. 2002;14(1):31-37.
22. Harrington LE, Most Rv R, Whitton JL, Ahmed R. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol. 2002;76(7):3329-3337.
23. Scholl SM, Balloul JM, Le Goc G, et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother. 2000;23(5):570-580.
24. Gilewski T, Adluri S, Ragupathi G, et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res. 2000;6(5):1693-1701.
25. Dong YB, Yang HL, Elliott MJ, McMasters KM. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors. Cancer Res. 2002;62(6):1776-1783.
26. Mercier S, Gahery-Segard H, Monteil M, et al. Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product. J Virol. 2002;76(6):2899-2911.
27. Jakubczak JL, Rollence ML, Stewart DA, et al. Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells. J Virol. 2001;75(6):2972-2981.
28. Nishida Y, Maeda Y, Hara A, et al. Adenovirus-mediated murine interferon-gamma receptor transfer enhances the efficacy of IFN-gamma in vivo. Biochem Biophys Res Commun. 2002;290(3):1042-1047.
29. Hamada K, Alemany R, Zhang WW, et al. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res. 1996;56(13):3047-3054.
30. Lammering G, Lin PS, Contessa JN, Hampton JL, Valerie K, Schmidt-Ullrich RK. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells. Int J Radiat Oncol Biol Phys. 2001;51(3):775-784.
31. Lee EJ, Jakacka M, Duan WR, et al. Adenovirus-directed expression of dominant negative estrogen receptor induces apoptosis in breast cancer cells and regression of tumors in nude mice. Mol Med. 2001;7(11):773-782.
32. Hamada K, Sakaue M, Alemany R, et al. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gynecol Oncol. 1996;63(2):219-227.
33. Liu Y, Chiriva-Internati M, Grizzi F, et al. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Ther. 2001;8(12):948-957.
34. Fujiwara T, Kataoka M, Tanaka N. Adenovirus-mediated p53 gene therapy for human cancer. Mol Urol. 2000;4(2):51-54.
35. Lane DP, Lain S. Therapeutic exploitation of the p53 pathway. Trends Mol Med. 2002;8(suppl 4):S38-S42.
36. Horowitz J. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications. Curr Opin Mol Ther. 1999;1(4):500-509.
37. Merritt JA, Roth JA, Logothetis CJ. Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. Semin Oncol. 2001;28(5 suppl 16):105-114.
38. Kuball J, Wen SF, Leissner J, et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol. 2002;20(4):957-965.
39. Weill D, Mack M, Roth J, et al. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. Chest. 2000;118(4):966-970.
40. Gomez-Navarro J, Curiel DT. Conditionally replicative adenoviral vectors for cancer gene therapy. Lancet Oncol. 2000;1:148-158.
41. Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic plafform. Lancet Oncol. 2002;3(1):17-26.
42. Fabra A, Parada C, Vinyals A, et al. Intravascular injections of a conditional replicative adenovirus (adl118) prevent metastatic disease in human breast carcinoma xenografts. Gene Ther. 2001;8(21):1627-1634.
43. Ring CJ. Cytolytic viruses as potential anti-cancer agents. J Gen Virol. 2002;83(pt 3):491-502.
44. Bauerschmitz GJ, Lam JT, Kanerva A, et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res. 2002;62(5):1266-1270.
45. Norman KL, Coffey MC, Hirasawa K, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther. 2002;13(5):641-652.
46. Martuza RL. Conditionally replicating herpes vectors for cancer therapy. J Clin Invest. 2000;105(7):841-846.
47. Jorgensen TJ, Katz S, Wittmack EK, et al. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia. 2001;3(5):451-456.
48. Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia. 1999;1(2):162-169.
49. Toda M, Martuza RL, Rabkin SD. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther. 2000;2(4):324-329.
50. Johannes L. The epithelial cell cytoskeleton and intracellular trafficking. I. Shiga toxin B-subunit system: retrograde transport, intracellular vectorization, and more. Am J Physiol Gastrointest Liver Physiol. 2002;283(1):G1-7.
51. Gerolami R, Uch R, Jordier F, et al. Gene transfer to hepatocellular carcinoma: transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors. Cancer Gene Ther. 2000;7(9):1286-1292.
52. O'Sullivan GC, Aarons SJ, Shanahan F. Mutant salmonella as vectors for gene therapy. Gastroenterology. 2001;121(1):224-226.
53. Guan J, Ma L, Wei L. Characteristics of ovarian cancer cells transduced by the bicistronic retroviral vector containing GM-CSF and HSV-TK genes. Chin Med J (Engl). 2001;114(2):147-151.
54. Schiller JT. Papillomavirus-like particle vaccines for cervical cancer. Mol Med Today. 1999;5(5):209-215.
55. Connett H. HPV vaccine moves into late stage trials. Nat Med. 2001;7(4):388.
56. Osen W, Peiler T, Ohlschlager P, et al. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine. 2001;19(30):4276-4286.
57. Muderspach L, Wilczynski S, Roman L, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res. 2000;6(9):3406-3416.
58. Marais DJ, Rose RC, Lane C, et al. Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia. J Med Virol. 2000;60(4):403-410.
59. Rooney CM, Aguilar LK, Huls MH, Brenner MK, Heslop HE. Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol. 2001;258:221-229.
60. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M. MUC1 and cancer. Biochim Biophys Acta. 1999;1455(2-3):301-313.
61. Heukamp LC, van der Burg SH, Drijfhout JW, Melief CJ, Taylor-Papadimitriou J, Offringa R. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice. Int J Cancer. 2001;91(3):385-392.
62. Heukamp LC, van Hall T, Ossendorp F, et al. Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope. J Immunother. 2002;25(1):46-56.
63. Miles BJ, Shalev M, Aguilar-Cordova E, et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001;12(16):1955-1967.
64. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol. 2002;20(8):2197-2207.
65. Horig H, Lee DS, Conkright W, et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother. 2000;49(9):504-514.
66. Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther. 2001;8(9):628-635.
67. O'Keefe DS, Uchida A, Bacich DJ, et al. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate. 2000;45(2):149-157.
68. Xie X, Zhao X, Liu Y, et al. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. Hum Gene Ther. 2001;12(5):549-561.
69. Gilbert SC, Schneider J, Hannan CM, et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous primeboost immunisation regimes. Vaccine. 2002;20(7-8):1039-1045.
70. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994;12:337-365.
71. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001;61(14):5544-5551.
72. Sung MW, Chen SH, Thung SN, et al. Intratumoral delivery of adenovirus-mediated interleukin-12 gene in mice with metastatic cancer in the liver. Hum Gene Ther. 2002;13(6):731-743.
73. Divino CM, Chen SH, Yang W, Thung S, Brower ST, Woo SL. Anti-tumor immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells. Breast Cancer Res Treat. 2000;60(2):129-134.
74. Chen SH, Pham-Nguyen KB, Martinet O, et al. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol Ther. 2000;2(1):39-46.
75. Belldegrun A, Tso CL, Zisman A, et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther. 2001;12(8):883-892.
76. Elzey BD, Siemens DR, Ratliff TL, Lubaroff DM. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer. 2001;94(6):842-849.
77. Chen B, Timiryasova TM, Gridley DS, Andres ML, Dutta-Roy R, Fodor I. Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumour immunotherapy. Cytokine. 2001;15(6):305-314.
78. Maio M, Fonsatti E, Lamaj E, et al. Vaccination of stage IV patients with allogeneic IL-4-or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother. 2002;51(1):9-14.
79. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol. 2000;18(23):3964-3973.
80. Tillman BW, de Gruijl TD, Luykx-de Bakker SA, et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol. 1999;162(11):6378-6383.
81. Schmitz V, Qian C, Ruiz J, et al. Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies. Gut. 2002;50(1):130-135.
82. Liu Y, Zhang X, Zhang W, et al. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity. Cancer Gene Ther. 2002;9(2):202-208.
83. Narvaiza I, Mazzolini G, Barajas M, et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol. 2000;164(6):3112-3122.
84. Ziller C, Stoeckel F, Boon L, Haegel-Kronenberger H. Transient blocking of both B7.1 (CD80) and B7.2 (CD86) in addition to CD40-CD40L interaction fully abrogates the immune response following systemic injection of adenovirus vector. Gene Ther. 2002;9(9):537-546.
85. Qian HN, Liu GZ, Cao SJ, Feng J, Ye X. The experimental study of ovarian carcinoma vaccine modified by human B7-1 and IFN-gamma genes. Int J Gynecol Cancer. 2002;12(1):80-85.
86. Tao G, Zou H, Hu J. Anti-tumor immune response to cervical carcinoma induced by costimulatory molecule B7 gene in mice [in Chinese]. Zhonghua Fu Chan Ke Za Zhi. 2001;36(2):111-114.
87. von Mehren M, Arlen P, Gulley J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res. 2001;7(5):1181-1191.
88. Hodge JW, Rad AN, Grosenbach DW, et al. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst. 2000;92(15):1228-1239.
89. Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. 2001;61(11):4497-4505.
90. Shankar P, Schlom J, Hodge JW. Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3). Vaccine. 2001;20(5-6):744-755.
91. Obermiller PS, Tait DL, Holt JT. Gene therapy for carcinoma of the breast: Therapeutic genetic correction strategies. Breast Cancer Res. 2000;2(1):28-31.
92. Randrianarison V, Marot D, Foray N, et al. BRCA1 carries tumor suppressor activity distinct from that of p53 and p21. Cancer Gene Ther. 2001;8(10):759-770.
93. Lee KY, Yoo CG, Han SK, Shim YS, Kim YW. The effects of transferring tumor suppressor gene p16INK4A to p16INK4A-deleted cancer cells. Korean J Intern Med. 1999;14(1):53-58.
94. Barnard DL. Technology evaluation: Sch-58500, Canji. Curr Opin Mol Ther. 2000;2(5):586-592.
95. Mizumoto M, Arii S, Furutani M, Mori A, Imamura M. A novel suicide gene therapy system for p53-mutated cells using a wild-type p53-specific promoter and Cre/loxP switch. Surg Today. 2002;32(1):53-58.
96. Bauerschmitz GJ, Nettelbeck DM, Kanerva A, et al. The flt-1 promoter for transcriptional targeting of teratocarcinoma. Cancer Res. 2002;62(5):1271-1274.
97. Bao R, Selvakumaran M, Hamilton TC. Targeted gene therapy of ovarian cancer using an ovarian-specific promoter. Gynecol Oncol. 2002;84(2):228-234.
98. Iwai M, Harada Y, Ishii M, et al. Suicide gene therapy of human hepatoma and its peritonitis carcinomatosis by a vector of replicative-deficient herpes simplex virus. Biochem Biophys Res Commun. 2002;291(4):855-860.
99. Carbone JE, Ohm DP. Immune dysfunction in cancer patients. Oncology (Huntingt). 2002;16(1 suppl 1):11-18.
100. Menetrier-Caux C, Bain C, Favrot MC, Duc A, Blay JY. Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes. Br J Cancer. 1999;79(1):119-130.
101. Sombroek CC, Stam AG, Masterson AJ, et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol. 2002;168(9):4333-4343.
102. Almand B, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6(5):1755-1766.
103. Andrews B, Shariat SF, Kim JH, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol. 2002;167(3):1475-1481.
104. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 2001;58(6):1008-1015.
105. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2(10):1096-1103.
106. Santin AD, Hermonat PL, Ravaggi A, Cannon MJ, Pecorelli S, Parham GP. Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol. 1999;20(3):177-181.
107. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res. 2001;23(2-3):263-272.
108. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999;5(10):2963-2970.
109. Tartour E, Mosseri V, Jouffroy T, et al. Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet. 2001;357(9264):1263-1264.
110. Baron C, Raposo G, Scholl SM, et al. Modulation of MHC class II transport and lysosome distribution by macrophage-colony stimulating factor in human dendritic cells derived from monocytes. J Cell Sci. 2001;114(pt 5):999-1010.
111. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193(6):727-740.
112. Wilson J, Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol. 2002;12(2):113-120.
113. Balkwill F, Mantovani A. Inflammation and cancer: back to virchow? Lancet. 2001;357(9255):539-545.
114. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998;58(22):4997-5001.
115. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000;42(1):73-78.
116. Mohammed SI, Knapp DW, Bostwick DG, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res. 1999;59(22):5647-5650.
117. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999;59(5):987-990.
118. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol. 2002;3(3):166-174.
119. Hirschowitz E, Hidalgo G, Doherty D. Induction of cyclo-oxygenase-2 in non-small cell lung cancer cells by infection with DeltaE1, DeltaE3 recombinant adenovirus vectors. Gene Ther. 2002;9(1):81-84.
120. Hirschowitz EA, Hidalgo GE, Doherty DE. Induction of cyclo-oxygenase-2 in non-small cell lung cancer cells by adenovirus vector information. Chest. 2002;121(suppl 3):32S.
121. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107(4):1183-1188.
122. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93(5):705-716.
123. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94(4):252-266.
124. Yamamoto Y, Gaynor RB. Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr Mol Med. 2001;1(3):287-296.
125. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001;107(3):241-246.
126. Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest. 2001;107(1):3-6.
127. Li JH, Chia M, Shi W, et al. Tumor-targeted gene therapy for nasopharyngeal carcinoma. Cancer Res. 2002;62(1):171-178.
128. Hemminki A. From molecular changes to customised therapy. Eur J Cancer. 2002;38(3):333-338.
129. Rosell R, Green M, Gumerlock P. Advances in the treatment of non-small cell lung cancer: molecular markers take the stage. Semin Oncol. 2001;28(1 suppl 2):28-34.
130. Duverger V, Sartorius U, Klein-Bauernschmitt P, Krammer PH, Schlehofer JR. Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type 2. Int J Cancer. 2002;97(5):706-712.
131. Nishizaki M, Meyn RE, Levy LB, et al. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res. 2001;7(9):2887-2897.
132. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1-10.
133. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the society for biological therapy. J Immunother. 2002;25(2):97-138.